Related references
Note: Only part of the references are listed.Cancer statistics, 2022
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2022)
Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO and OH (CCO) Joint Guideline Update
Nasser H. Hanna et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC
Mark A. Socinski et al.
JOURNAL OF THORACIC ONCOLOGY (2021)
Inhibition of stromal biglycan promotes normalization of the tumor microenvironment and enhances chemotherapeutic efficacy
Li Cong et al.
BREAST CANCER RESEARCH (2021)
Low-Dose Anti-Angiogenic Therapy Sensitizes Breast Cancer to PD-1 Blockade
Qian Li et al.
CLINICAL CANCER RESEARCH (2020)
Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update
Nasser H. Hanna et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Experimental study of the vascular normalization window for tumors treated with apatinib and the efficacy of sequential chemotherapy with apatinib in lung cancer-bearing mice and patients
Mingtao Liu et al.
CANCER MEDICINE (2020)
Low-Dose Apatinib Optimizes Tumor Microenvironment and Potentiates Antitumor Effect of PD-1/PD-L1 Blockade in Lung Cancer
Sha Zhao et al.
CANCER IMMUNOLOGY RESEARCH (2019)
Optical-resolution photoacoustic microscopy for monitoring vascular normalization during anti-angiogenic therapy
Hui-Chao Zhou et al.
PHOTOACOUSTICS (2019)
Carbonic anhydrase 2 (CAII) supports tumor blood endothelial cell survival under lactic acidosis in the tumor microenvironment
Dorcas A. Annan et al.
CELL COMMUNICATION AND SIGNALING (2019)
Optimal Scheduling of Bevacizumab and Pemetrexed/Cisplatin Dosing in Non-Small Cell Lung Cancer
Benjamin K. Schneider et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2019)
Revisiting Bevacizumab
Diane-Charlotte Imbs et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2018)
Improving immune-vascular crosstalk for cancer immunotherapy
Yuhui Huang et al.
NATURE REVIEWS IMMUNOLOGY (2018)
Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation
Elizabeth Allen et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Apelin as a marker for monitoring the tumor vessel normalization window during antiangiogenic therapy
Li Zhang et al.
CANCER SCIENCE (2016)
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
Louis Fehrenbacher et al.
LANCET (2016)
Tumour endothelial cells in high metastatic tumours promote metastasis via epigenetic dysregulation of biglycan
Nako Maishi et al.
SCIENTIFIC REPORTS (2016)
The effect of chemotherapeutic agents on tumor vasculature in subcutaneous and orthotopic human tumor xenografts
Andrea S. Fung et al.
BMC CANCER (2015)
Targeting the tumor vasculature to enhance T cell activity
Evripidis Lanitis et al.
CURRENT OPINION IN IMMUNOLOGY (2015)
VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors
Thibault Voron et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2015)
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer
Julie Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Inhibition of immune checkpoints and vascular endothelial growth factor as combination therapy for metastatic melanoma: an overview of rationale, preclinical evidence, and initial clinical data
Patrick A. Ott et al.
FRONTIERS IN ONCOLOGY (2015)
Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial
Edward B. Garon et al.
LANCET (2014)
Tissues in Different Anatomical Sites Can Sculpt and Vary the Tumor Microenvironment to Affect Responses to Therapy
Christel Devaud et al.
MOLECULAR THERAPY (2014)
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Paul C. Tumeh et al.
NATURE (2014)
Oncology Meets Immunology: The Cancer-Immunity Cycle
Daniel S. Chen et al.
IMMUNITY (2013)
Immunogenicity of Murine Solid Tumor Models as a Defining Feature of In Vivo Behavior and Response to Immunotherapy
Melissa G. Lechner et al.
JOURNAL OF IMMUNOTHERAPY (2013)
Notch-dependent VEGFR3 upregulation allows angiogenesis without VEGF-VEGFR2 signalling
Rui Benedito et al.
NATURE (2012)
Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner
Vikash P. Chauhan et al.
NATURE NANOTECHNOLOGY (2012)
Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy
Yuhui Huang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Delivery of Molecular and Nanoscale Medicine to Tumors: Transport Barriers and Strategies
Vikash P. Chauhan et al.
ANNUAL REVIEW OF CHEMICAL AND BIOMOLECULAR ENGINEERING, VOL 2 (2011)
Antiangiogenic Agents Can Increase Lymphocyte Infiltration into Tumor and Enhance the Effectiveness of Adoptive Immunotherapy of Cancer
Rajeev K. Shrimali et al.
CANCER RESEARCH (2010)
Transcription factor 8 activates R-Ras to regulate angiogenesis
Takayuki Inuzuka et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2009)
Anti-PIGF inhibits growth of VEGF(R)-Inhibitor-Resistant tumors without affecting healthy vessels
Christian Fischer et al.
CELL (2007)
A vascular endothelial growth factor receptor-2 inhibitor enhances antitumor immunity through an immune-based mechanism
Elizabeth A. Manning et al.
CLINICAL CANCER RESEARCH (2007)
Revacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy
Paxton V. Dickson et al.
CLINICAL CANCER RESEARCH (2007)
Scheduling of radiation with angiogenesis inhibitors anginex and avastin improves therapeutic outcome via vessel normalization
Ruud P. M. Dings et al.
CLINICAL CANCER RESEARCH (2007)
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer
Alan Sandler et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
VEGF controls endothelial-cell permeability by promoting the β-arrestin-dependent endocytosis of VE-cadherin
Julie Gavard et al.
NATURE CELL BIOLOGY (2006)
Pathophysiological consequences of VEGF-induced vascular permeability
SM Weis et al.
NATURE (2005)
Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy
RK Jain
SCIENCE (2005)
Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors
RT Tong et al.
CANCER RESEARCH (2004)
Imaging of angiogenesis: from microscope to clinic
DM McDonald et al.
NATURE MEDICINE (2003)
Probing the structural and molecular diversity of tumor vasculature
R Pasqualini et al.
TRENDS IN MOLECULAR MEDICINE (2002)
Clinical translation of angiogenesis inhibitors
R Kerbel et al.
NATURE REVIEWS CANCER (2002)
Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors
S Morikawa et al.
AMERICAN JOURNAL OF PATHOLOGY (2002)
Molecular mechanisms of blood vessel growth
EM Conway et al.
CARDIOVASCULAR RESEARCH (2001)
Share Paper
